Surmodics gets FDA nod for Telemark microcatheter

Surmodics plans to make the product available for U.S. distribution in the coming months. (FDA)

Surmodics has received FDA clearance to sell its Telemark .014” coronary and peripheral support microcatheter. The 510(k) nod positions Surmodics to start shipping a device designed for use in the treatment of complex coronary and peripheral lesions.

Telemark brings together two Surmodics’ technologies, namely its Xtreme composite shaft and Pristyne hydrophilic coating. Surmodics thinks this gives the microcatheter properties that will make it a valuable tool for doctors. 

“Our Telemark microcatheter incorporates advanced technology that enables an exceedingly low crossing profile, excellent trackability and resistance to kinking, even in complex coronary and peripheral lesions, where there is still a great market need,” Surmodics CEO Gary Maharaj said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Surmodics had hoped to secure the 510(k) clearance before the end of 2017 but was forced to push back its timeline by a request for more data from the agency. The company responded by refiling late last year and has now been rewarded with a 510(k) clearance. 

Securing the approval sets Surmodics up to embark on the next stage of the lifecycle of the device. Surmodics plans to make the product available for U.S. distribution in the coming months. And it has previously discussed entering into deals covering the device. Talking last year, Maharaj said the talks would advance once the approval was in place.

Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.